James Thompson
Neurology · Skowhegan, MENPI 1306928445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,101 and has fallen 75.8% since, to $266 in 2022.
Across 180 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$517
- UCB, Inc.$358
- Acadia Pharmaceuticals Inc$266
- SK Life Science, Inc.$199
- Novartis$164
- Amneal Pharmaceuticals LLC$108
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,058100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $517 |
| UCB, Inc. | 23 | $358 |
| Acadia Pharmaceuticals Inc | 18 | $266 |
| SK Life Science, Inc. | 11 | $199 |
| Novartis | 9 | $164 |
| Amneal Pharmaceuticals LLC | 7 | $108 |
| Adamas Pharmaceuticals, Inc. | 5 | $105 |
| Biogen | 5 | $103 |
| Supernus Pharmaceuticals, Inc. | 6 | $96 |
| EMD Serono, Inc. | 6 | $89 |
| GE HealthCare | 4 | $77 |
| CSL Behring | 3 | $72 |
| AstraZeneca(2 entities) | 4 | $63 |
| Akcea Therapeutics, Inc. | 3 | $61 |
| Grifols USA, LLC | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 4 | $58 |
| Kyowa Kirin, Inc. | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Sanofi | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| Amgen(2 entities) | 2 | $42 |
| Lilly USA, LLC | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Eisai Inc. | 2 | $35 |
| Livanova USA, Inc. | 2 | $32 |
| Boston Scientific | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 2 | $26 |
| Avion Pharmaceuticals | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Pfizer | 1 | $14 |
| Medtronic | 1 | $14 |
How this compares
$3,069 in reported general payments places this provider in the 75th percentile of 69 neurology providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 40 | $251,891 |
| VumerityDiroximel Fumarate | 25 | $214,856 |
| Nurtec OdtRimegepant Sulfate | 81 | $125,156 |
| AubagioTeriflunomide | 13 | $115,902 |
| BriviactBrivaracetam | 64 | $107,115 |
| AptiomEslicarbazepine Acetate | 31 | $62,894 |
| Oxtellar XrOxcarbazepine | 38 | $38,885 |
| Aimovig AutoinjectorErenumab-Aooe | 41 | $37,040 |
| Lacosamide | 154 | $36,089 |
| Emgality PenGalcanezumab-Gnlm | 51 | $35,643 |
| Lamotrigine ErLamotrigine | 97 | $31,918 |
| Trokendi XrTopiramate | 13 | $31,834 |
| QuliptaAtogepant | 22 | $28,145 |
| Dimethyl Fumarate | 32 | $24,310 |
| TrileptalOxcarbazepine | 11 | $20,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $266 | $251,89140 claims |
| BiogenVumerity | $103 | $214,85625 claims |
| PfizerNurtec Odt, Relpax | $14 | $136,72594 claims |
| SanofiAubagio | $45 | $115,90213 claims |
| UCB, Inc.Briviact | $358 | $107,11564 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr | $96 | $70,71951 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $58 | $62,89431 claims |
| AbbVieQulipta | $517 | $28,14522 claims |
| Amneal Pharmaceuticals LLCRytary | $108 | $17,37930 claims |
| Upsher-smith Laboratories LLCTopiramate | $21 | $3,038135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 neurology providers in Maine.
Other neurology in Skowhegan
- Carlo BrognaSkowhegan$76
- Muhammad AlamSkowhegan$22
- Anthony KnoxYork$380K
- John DolanPortland$370K
- Heidi HenningerScarborough$350K
- Aashoo MentreddiYork$176K
- Alexander AbudRockport$113K
- Alexandra DegenhardtRockport$65K
- Alison DaigleSouth Portland$50K
- Helia MaghziScarborough$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.